Analyst Price Target is $58.33
▲ +0.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Integra LifeSciences in the last 3 months. The average price target is $58.33, with a high forecast of $75.00 and a low forecast of $48.00. The average price target represents a 0.18% upside from the last price of $58.23.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in Integra LifeSciences. This Hold consensus rating has held steady for over two years.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.